OBJECTIVES: To establish the economic value of revising an arteriovenous graft (AVG) with a stent-graft versus balloon angioplasty using data from the Gore REVISE Clinical Randomised Controlled trial along with cost data specific to the treatment setting in England as Hemodialysis patients with AVG implants can experience AVG stenosis and thrombosis requiring revision. METHODS: The REVISE Clinical Study (NCT00737672) was a prospective, multicenter, RCT in the U.S. comparing the GORE^® VIABAHN^® Endoprosthesis with Heparin Bioactive Surface (N=131) versus angioplasty (N=138) for treatment of dysfunctional or thrombosed prosthetic AVGs and followed patients for 2-years. The trial collected resource utilization data used in the economic analysis, including the number of devices used and the types of repeat interventions performed. Procedure cost data is from the 2014/2015 NHS England Reference Costs. The 2015 UK list prices are used for the GORE^® VIABAHN^® Device and prices for other stent-grafts used in repeat interventions are from a 2015 UK market analysis report (^©